1. Home
  2. AVR vs GLO Comparison

AVR vs GLO Comparison

Compare AVR & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVR
  • GLO
  • Stock Information
  • Founded
  • AVR 1999
  • GLO 2006
  • Country
  • AVR Australia
  • GLO United States
  • Employees
  • AVR N/A
  • GLO N/A
  • Industry
  • AVR
  • GLO Finance/Investors Services
  • Sector
  • AVR
  • GLO Finance
  • Exchange
  • AVR NYSE
  • GLO Nasdaq
  • Market Cap
  • AVR 215.6M
  • GLO 220.0M
  • IPO Year
  • AVR 2024
  • GLO N/A
  • Fundamental
  • Price
  • AVR $6.18
  • GLO $5.28
  • Analyst Decision
  • AVR Strong Buy
  • GLO
  • Analyst Count
  • AVR 4
  • GLO 0
  • Target Price
  • AVR $16.50
  • GLO N/A
  • AVG Volume (30 Days)
  • AVR 156.0K
  • GLO 170.5K
  • Earning Date
  • AVR 01-01-0001
  • GLO 01-01-0001
  • Dividend Yield
  • AVR N/A
  • GLO 11.38%
  • EPS Growth
  • AVR N/A
  • GLO N/A
  • EPS
  • AVR N/A
  • GLO N/A
  • Revenue
  • AVR $2,826,588.00
  • GLO N/A
  • Revenue This Year
  • AVR N/A
  • GLO N/A
  • Revenue Next Year
  • AVR N/A
  • GLO N/A
  • P/E Ratio
  • AVR N/A
  • GLO N/A
  • Revenue Growth
  • AVR N/A
  • GLO N/A
  • 52 Week Low
  • AVR $5.10
  • GLO $4.08
  • 52 Week High
  • AVR $6.29
  • GLO $5.18
  • Technical
  • Relative Strength Index (RSI)
  • AVR N/A
  • GLO 47.76
  • Support Level
  • AVR N/A
  • GLO $5.22
  • Resistance Level
  • AVR N/A
  • GLO $5.35
  • Average True Range (ATR)
  • AVR 0.00
  • GLO 0.06
  • MACD
  • AVR 0.00
  • GLO -0.00
  • Stochastic Oscillator
  • AVR 0.00
  • GLO 27.50

About AVR ANTERIS TECHNOLOGIES GLOBAL CORP

Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

About GLO Clough Global Opportunities Fund

Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.

Share on Social Networks: